Recent Finacing
Recent Raise
NephroDI is a Seattle-based pharma developing oral AMPK-activating small molecules (NDI-5001/NDI-5033) that enhance renal water reabsorption and urine concentration for pediatric congenital nephrogenic diabetes insipidus, moving toward clinical development.
